Skip to main content
SpringerLink
Log in

Sequenztherapie in der Zweitlinie

Palliative systemische Therapie des hepatozellulären Karzinoms

  • Gastroonkologie
  • Fortbildung
  • Published:
Im Fokus Onkologie Aims and scope

Hepatozelluläre Karzinome (HCC) gehören zu den häufigsten Tumoren in der westlichen Welt. Bis 2017 war die einzige zugelassene systemische Therapieoption Sorafenib. Innerhalb der vergangenen drei Jahre erlangten weitere Substanzen die europäische Marktzulassung, die das Therapiespektrum in der Erstlinie erweitern und nun erstmals auch eine systemische Sequenztherapie beim HCC ermöglichen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Llovet JM et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90

    Article  CAS  Google Scholar 

  2. Cheng AL et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34

    Article  CAS  Google Scholar 

  3. McNamara MG et al. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma - a meta-analysis. Eur J Cancer. 2018;105:1–9

    Article  CAS  Google Scholar 

  4. Reiss KA et al. Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study. J Clin Oncol. 2017;35(31):3575–81

    Article  CAS  Google Scholar 

  5. Rimola J et al. Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events. Hepatology. 2017. https://doi.org/10.1002/hep.29515

    Google Scholar 

  6. Bruix J et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. J Hepatol. 2017;67(5):999–1008

    Article  CAS  Google Scholar 

  7. Llovet JM et al. Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res. 2012;18(8):2290–300

    Article  CAS  Google Scholar 

  8. Finn RS et al. Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]. Ann Oncol. 2018;29(suppl 8): Abstr 59PD

    Google Scholar 

  9. Cheng A-L et al. Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC). J Clin Oncol. 2017;35(suppl 15):Abstr 4001

    Article  Google Scholar 

  10. Okusaka T et al. Safety and efficacy of lenvatinib by starting dose (8 mg or 12 mg) based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT. J Clin Oncol. 2019;37(suppl 4):Abstr 316

    Article  Google Scholar 

  11. Vogel A et al. Health-related quality of Life (HRQOL) and disease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib (SOR). Ann Oncol. 2017;28(suppl_5):v209–68

    Article  Google Scholar 

  12. Alsina A et al. Subsequent anticancer medication following first-line lenvatinib: A posthoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma. J Clin Oncol. 2019;37(suppl 4):Abstr 371

    Article  Google Scholar 

  13. Bruix J et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66

    Article  CAS  Google Scholar 

  14. Finn RS et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. J Hepatol. 2018;69(2):353–8

    Article  CAS  Google Scholar 

  15. Teufel M et al. Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma. Gastroenterology. 2019;156(6):1731–41

    Article  CAS  Google Scholar 

  16. Abou-Alfa GK et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018;379(1): 54–63

    Article  CAS  Google Scholar 

  17. Zhu AX et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16(7):859–70

    Article  CAS  Google Scholar 

  18. Zhu AX et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282–96

    Article  CAS  Google Scholar 

  19. Brandi G et al. Ramucirumab for patients with hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib treatment: exploratory analysis of REACH-2 trial results by albumin-bilirubin grade and Child-Pugh score. EASL HCC Summit. 2019;Abstr OP–07

    Google Scholar 

  20. El-Khoueiry AB et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–502

    Article  CAS  Google Scholar 

  21. Zhu AX et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940–52

    Article  Google Scholar 

  22. Finn RS et al. Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2019;37(suppl):Abstr 4004

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Anna Saborowski

  2. Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Carl-Neuberg Str. 1, 30625, Hannover, Deutschland

    Arndt Vogel

Authors
  1. Anna Saborowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arndt Vogel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arndt Vogel.

Additional information

Interessenkonflikte

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrags von keinen wirtschaftlichen Interessen leiten ließen. Die Autoren legen mögliche Interessenkonflikte offen: Prof. Dr. med. Arndt Vogel erhielt Honoraria von Bayer, Roche, Lilly, EISAI, Ipsen, BMS und MSD. Dr. med. Anna Saborowski erhielt Reisekostenzuschüsse von Ipsen, Roche und Novartis.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saborowski, A., Vogel, A. Palliative systemische Therapie des hepatozellulären Karzinoms. Im Focus Onkologie 22, 19–26 (2019). https://doi.org/10.1007/s15015-019-0102-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-019-0102-x

Search

Navigation